Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HLX07 in nonsquamous non-small cell lung cancer with high EGFR expression (status unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HLX07 (HLX07)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: HLX07, nsqNSCLC, High EGFR Expression | Phase 2 | Status: UNKNOWN